Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors

American Journal of Health-System Pharmacy

Volumn 63, Issue 23, 2006, Pages 2340-2348

  Utecht, Kyle N ^a   Hiles, Jon J ^a   Kolesar, Jill ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b University of Wisconsin Health   (United States)

Author keywords

Availability; Blood levels; Cyclosporine; Dosage; Drugs; Graft rejection; Immunosuppressive agents; Metabolism; Pharmacogenetics; Pharmacokinetics; Polymorphism; Tacrolimus; Toxicity; Transplantation

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; CYTOCHROME P450; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; GLUCOSE; GLYCOPROTEIN P; IMMUNOSUPPRESSIVE AGENT; ISOENZYME; MULTIDRUG RESISTANCE PROTEIN 1; TACROLIMUS;

ALLELE; AREA UNDER THE CURVE; CYP3A4 GENE; CYP3A5 GENE; DISEASE SEVERITY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG METABOLISM; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRACT; GENE; GENETIC MARKER; GENETIC POLYMORPHISM; GINGIVA HYPERPLASIA; GLUCOSE BLOOD LEVEL; GRAFT REJECTION; HEADACHE; HIRSUTISM; HOMOZYGOTE; HUMAN; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOMAGNESEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LEUKOCYTOSIS; LIVER; LIVER TOXICITY; MDR1 GENE; NEPHROTOXICITY; PGP GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS; RECIPIENT; REVIEW; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREMOR;

EID: 33845232219     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060080     Document Type: Review

References (36)

1. Organ Procurement and Transplantation Network. Data reports: national data. www.optn.org/latestData/step2.asp (accessed 2006 Sep 1).
2. Immunosuppressive therapy for renal transplantation in adults. Technology appraisal no. 85. London, England: National Institute for Clinical Excellence; 2004.
3. Sandimmune (cyclosporine) package insert. East Hanover, NJ: Novartis Pharmaceuticals; 2005.
4. Neoral (cyclosporine, modified) package insert. East Hanover, NJ: Novartis Pharmaceuticals; 2005.
5. Prograf (tacrolimus) package insert. Deerfield, IL: Astellas Pharma US; 2006.
6. Saeki T, Ueda K, Tanigawara Y et al. Human P-glycoprotein transports cyclosporine A and FK506. J Biol Chem. 1993; 268:6077-80.
7. Hashida T, Masuda S, Uemoto S et al. Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor small bowel recipients. Clin Pharmacol Ther. 2001; 69:308-16.
8. Webster A, Woodroffe RD, Taylor RS et al. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients (Cochrane Review). In: The Cochrane Library, Issue 2, 2006. Chichester: Wiley.
9. Clase CM, Mahalati K, Kiberd BA et al. Adequate early cyclosporin exposure is critical to prevent allograft rejection: patients monitored by absorption profiling. Am J Transplant. 2002; 2:789-95.
10. Anglicheau D, Thervet E, Etienne I et al. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther. 2004; 75:422-33.
11. Hesselink DA, van Gelder T, van Schalk RH et al. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin Pharmacol Ther. 2004; 76:545-56.
12. Ball SE, Scatina J, Kao J et al. Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin Pharmacol Ther. 1999; 66:288-94.
13. Sata F, Sapone A, Elizondo G et al. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther. 2000; 67:48-56.
14. Hesselink DA, van Schaik RH, Heiden IP et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and the pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther. 2003; 74:245-54.
15. Kuehl P, Zhang J, Lin Y et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001; 27:383-91.
16. Husert E, Haberl M, Burk O et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics. 2001; 11:773-9.
17. Lamba JK, Lin YS, Shuetz EG et al. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 2002; 54:1271-94.
18. Ameyaw MM, Regateiro F, Li T et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics. 2001; 11:217-21.
19. Mourad M, Mourad G, Wallemacq P et al. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. Transplantation. 2005; 80:977-84.
20. Mai I, Stömer E, Goldammer M et al. MDR1 haplotypes do not affect the steady-state pharmacokinetics of cyclosporine in renal transplant patients. J Clin Pharmacol. 2003; 43:1101-7.
21. Hoffmeyer S, Burk O, von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci. 2000; 97:3473-8.
22. Goto M, Musada S, Sato H et al. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics. 2002; 12:451-7.
23. Anglicheau D, Verstuyft C, Laurent-Puig P et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol. 2003; 14:1889-96.
24. Kim RB, Leak BF, Choo EF et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001; 70:189-99.
25. Tanabe M, Ieiri I, Nagata N et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther. 2001; 297:1137-43.
26. Zhang X, Liu Z, Zheng J et al. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation. Clin Transplant. 2005; 19:638-43.
27. Yates CR, Zhang W, Song P et al. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol. 2003; 43:555-64.
28. Haufroid V, Mourad M, van Kerckove V et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics. 2004; 14:147-54.
29. Kreutz R, Zücher H, Kain S et al. The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patient. Pharmacogenetics. 2004; 14:665-71.
30. Tada H, Tsuchiya N, Satoh S et al. Impact of CYP3A5 and MDR1 (ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplant Proc. 2005; 37:1730-2.
31. Tsuchiya N, Satoh S, Tada H et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation. 2004; 78:1182-7.
32. MacPhee IA, Fredericks S, Tai T et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant. 2004; 4:914-9.
33. MacPhee IA, Fredericks S, Mohamed M et al. Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. Transplantation. 2005; 79:499-502.
34. Thervet E, Anglicheau D, King B et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation. 2003; 76:1233-5.
35. Chen X, Sullivan PF. Single nucleotide polymorphism genotyping: biochemistry, protocol, cost and throughput. Pharmacogenomics J. 2003; 3:77-96.
36. USA Today. Roche gene chip brings tailored medicine nearer. www.usatoday.com/tech/news/techinnovations/2003-06-25-gene-chips_x.htm (accessed 2006 Sep 1).